TABLE 1.
Patient characteristics and statistics
| Progressive‐free survival (PFS) | Overall survival (OS) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Logrank p | Cox p | HR | (95%CI) | Fig. | Logrank p | Cox p | HR | (95%CI) | Fig. | |||
| Response | CR vs. PR vs. SD vs. PD | (4 vs. 11 vs. 8 vs. 27) | n.a. | n.a. | ||||||||
| Physical | ||||||||||||
| Age | 71.6 (69.5–77.1) | |||||||||||
| <73.3 vs. > =73.3 | (23 vs. 27) | 0.0047 | 0.09 | 1.69 | (0.91–3.72) | 3A | 0.0042 | 0.12 | 1.57 | (0.85–4.68) | 3B | |
| Sex | Male vs. female | (31 vs. 19 ) | 0.7 | 0.95 | ||||||||
| Body mass index (BMI) | 22.3 (19.5–23.9) | |||||||||||
| <22.3 vs. > =22.3 | (25 vs. 25) | 0.42 | 0.61 | |||||||||
| Clinical courses | ||||||||||||
| Duration till pembrolizumab after recurrence | 139.5 (7–802) | |||||||||||
| <139.5 vs. > =139.5 | (25 vs. 25) | 0.73 | 0.71 | |||||||||
| Laboratory data | ||||||||||||
| Neutrophil‐to‐lymphocyte ratio (NLR) | 2.7 (2.2–4.7) | |||||||||||
| <2.63 vs. > =2.63 | (24 vs. 26) | 0.0056 | 0.06 | 1.87 | (0.97–3.88) | 3C | 0.0054 | 0.03 | 2.22 | (1.12–6.75) | 3D | |
| Platelet‐to‐lymphocyte ratio (PLR) | 189.9 (127.2–257.8) | |||||||||||
| <189.9 vs. > =189.9 | (25 vs. 25) | 0.74 | 0.066 | |||||||||
| Lymphocyte‐to‐monocyte ratio (LMR) | 4.1 (2.6–6.5) | |||||||||||
| <4.1 vs. > =4.1 | (25 vs. 25) | 0.44 | 0.099 | |||||||||
| Metastases before pembrolizumab | ||||||||||||
| Lung metastasis | No vs. yes | (35 vs. 15) | 0.22 | 0.64 | ||||||||
| Liver metastasis | No vs. yes | (40 vs. 10) | 0.11 | S1A | 0.041 | S1B | ||||||
| Bone metastasis | No vs. yes | (44 vs. 6) | 0.062 | 0.43 | ||||||||
| Lymph node metastasis | No vs. yes | (25 vs. 25) | 0.96 | 0.59 | ||||||||
| Peritoneal metastasis | No vs. yes | (44 vs. 6) | 0.96 | 0.96 | ||||||||
| Visceral metastasis | No vs. yes | (23 vs. 27) | 0.0075 | S1C | 0.13 | S1D | ||||||
| Adverse effect (AE) | No AE vs. AE of all grade | (23 vs. 27) | 0.0013 | S1E | 0.098 | S1F | ||||||
| No AE and AE of grade 1–2 vs. AE of grade 3 | (42 vs. 8) | 0.35 | 0.23 | |||||||||
| Pathological factors | ||||||||||||
| Special variant | No vs. yes | (34 vs. 16) | 0.69 | 0.092 | ||||||||
| Squamous differentiation | No vs. yes | (37 vs. 13) | 0.51 | 0.17 | ||||||||
| PD‐L1 expression | Low vs. high | (37 vs. 13) | 0.021 | 0.06 | 1.85 | (0.95–4.71) | 4A | 0.0013 | 0.01 | 2.72 | (1.78–35.03) | 4B |
| CD8+ lymphocytes | 46.2 (25.8–166.9) | |||||||||||
| <46.2 vs. > =46.2 | (26 vs. 24) | 0.054 | 0.27 | |||||||||
| p16(CDKN2A) homozygous deletion in FISH | Loss vs. retained | (30 vs. 30) | 0.30 | 0.35 | ||||||||
Italic indicates no significance of p value; Bold indicates significance of p value.
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PD‐L1, programmed cell death ligand‐1.